Market Access Service
From Discovery / Non-Clinical - Strategy and Consulting
The key to unlocking market access, is the ability to look beyond the science, to understand the market dynamics that will shape the future and drive value. To gain market access in pharma and remain competitive, pharmaceutical and medical technology manufacturers must be able to demonstrate clinical and economic evidence to providers, healthcare decision-makers and payers.
In the past, market access for a medicine depended...
In the past, market access for a medicine depended almost exclusively on efficacy and safety. These factors are still critical, but today, clinical differentiation and its effects on healthcare outcomes and resource utilization / optimization require more comprehensive approaches. Today, more than ever, pharmaceutical companies must demonstrate how a new drug improves patient outcomes, reduces the burden of the healthcare system as a whole and is worth its price. To satisfy these criteria, pharmaceutical manufacturers have gradually expanded their strategies ‘beyond the pill’ to build initiatives that take a more holistic view of patient treatment, provide better real-life evidence and therefore a stronger value proposition for decision makers.
For payers and market access stakeholders, the medicine value proposition encompasses the optimal combination of disease need, clinical efficacy and economic impact that achieves market access at an optimal price, in the appropriate setting, by validating and communicating the need for treatment and the value of utilizing the medicine in question in the right setting and to the right patient. To do so, market access activities have expanded significantly beyond pricing and reimbursement, and include other elements such us digital therapeutics, better integration of health/patient reported outcomes in healthcare decisions, or even value-based strategies amongst others.
In the increasing yet infant space of digital therapeutics, the challenges start early on when trying to reconcile the technology, the therapeutic objectives and the regulatory requirements for commercialization. The implications of MDR, go far beyond regulatory compliance, as it can impact the go to market strategies and associated revenue streams. Additionally, can hamper the potential data monetization strategies when appropriate, as well as other growth aspiration, and we look at it from that point of view, and can advise you on best alternatives according to your company and solution’s reality.
We can help you navigate the increasingly complicated legislative and market environment. Each stakeholder has their own particular interest in a product, and we can help you communicate the value of your product to stakeholders.
Customer reviews
No reviews were found for Market Access Service. Be the first to review!